Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
8 hedge funds and large institutions have $856K invested in Altamira Therapeutics Ltd in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
5.71% less ownership
Funds ownership: 25.93% → 20.22% (-5.7%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
44% less capital inflows, than outflows
Capital inflows: $612K | Capital outflows: $1.09M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$496K |
| 2 |
Wedbush Securities
Los Angeles,
California
|
+$52.8K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$21.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$21.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$21.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sofinnova Investments
Menlo Park,
California
|
-$844K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$106K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$45K |
| 4 |
Virtu Financial
New York
|
-$35K |
| 5 |
Two Sigma Securities
New York
|
-$33K |
CYTO Hedge Fund Activity: Q2 2018 in Review
8 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q2 2018, worth a combined $856K — down 66% from $2.54M a quarter earlier.
Fund positioning in CYTO was balanced in Q2 2018: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $496K. The largest seller was Sofinnova Investments, cutting an estimated $844K.
- 8 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $856K of Altamira Therapeutics Ltd stock for Q2 2018, down 66% quarter-over-quarter.
- 3 funds opened new Altamira Therapeutics Ltd positions in Q2 2018 and 3 closed out, a net change of 0 holders.
- The largest Altamira Therapeutics Ltd buyer in Q2 2018 was Morgan Stanley, an estimated $496K added.
- The largest Altamira Therapeutics Ltd seller in Q2 2018 was Sofinnova Investments, an estimated $844K sold.
Based on aggregated 13F filings for Q2 2018.